×

Biotech and Pharmaceuticals Pharmaceuticals

  • cancer_treatment_200.jpg

    Here are some snap biotech and drug stock judgments after a weekend spent at the American Society of Clinical Oncology annual meeting.

  • Healthcare cost

    Workplace insurers are used to making billions of dollars in payments each year. Now they are dealing with another fast-growing cost — payouts to workers with routine injuries who have been treated with strong painkillers.

  • Shanghai stock exchange

    China stocks may trade lower on Thursday, weighed down by uncertainties about the global economy and China's own fiscal policy response.

  • stethoscope_money_200.jpg

    The SPDR Health Care Select Sector exchange-traded fund is less than a sneeze from its recent highs, and some bulls are looking for it to pop.

  • There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.

  • dollar-bills-200.jpg

    Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.

  • arena_pharm.jpg

    An experimental obesity pill from Arena Pharmaceuticals won the support of U.S. advisers on Thursday, as public health advocates push for new solutions to the nation's growing obesity epidemic.

  • The "Mad Money" host learns more about this biotechnology company, which he thinks is a great speculative stock.

  • Johnson & Johnson

    Few stock sectors are as reliable as drugs and health care, and astute investors know that companies such as Merck, Pfizer, and Abbott Laboratories have delivered healthy returns over the years. One stock that investors have become less enamored with, however, is Johnson & Johnson.

  • In the immortal words of Barbra Streisand, people who need people are the luckiest people in the world. But what about the rest of us? We don’t all have what it takes to be gregarious, and outgoing, and one’s ability to be sociable, or lack thereof, can affect the type of employment one ends up taking.The extroverted have a bevy of jobs that let them press the flesh. There are sales, management, life coaching, and any number of other jobs that demand constant interaction with others. On the othe

    Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.

  • MLB baseballs seen through the netting of a basket

    The makers of a deer antler velvet product are suing Major League Baseball for libel after the league told players to stop taking the performance enhancer so as not to risk testing positive for a steroid that wasn't listed as an ingredient.

  • The “Mad Money” host offers his earnings expectations for Time Warner, CVS Caremark, Garmin, Allergan and Clorox.

  • pfizer_hq.jpg

    The largest U.S. drugmaker said its net income fell in the latest period as sales declined after the company lost its exclusivity on the cholesterol drug Lipitor at the end of November.

  • The "Mad Money" host shares his earnings expectations for Biogen Idec, Cummins, Emerson Electric and Chesapeake Energy.

  • merck_logo.jpg

    Merck said Friday that its first-quarter profit jumped 67 percent despite lower-than-expected sales, due to lower spending on production, marketing and research as well as an arbitration charge a year ago.

  • The "Mad Money" host shares his earnings expectations for International Paper, Procter & Gamble and V.F. Corp.

  • Amazon.com

    The "Mad Money" host reveals his earnings expectations for Celgene, Exxon-Mobil, Amazon.com, Deckers Outdoor and Zynga.

  • Eli Lilly's CEO on Prescription for Profits

    John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.

  • Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.

  • Amylin

    Amylin Pharmaceuticals, which spurned a $3.5 billion takeover bid from Bristol-Myers Squibb and is fending off a lawsuit from activist investor Carl Icahn, started reaching out to potential buyers last week, sources familiar with the situation said on Sunday.